1a. Objectives (from AD-416):
To develop a panel of monoclonal antibodies that will be used to develop sensitive immunoassays for detection of multiple serotypes of botulinum neurotoxin.
1b. Approach (from AD-416):
Monoclonal anti-toxin antibodies for serotypes B and E will be developed using chemical cell fusion methods following immunization with toxoids, toxins, or recombinant peptides. In addition, antibodies to nontoxin associated proteins will be developed. The monoclonal antibodies will be supplied to DHS contractors and other collaborating federal laboratories in order to format sensitive immunoassays for toxin identification. Documents Reimbursable with U.S Department of Homeland Security. Log 40768. Formerly 5325-42000-043-06R (4/11).
3. Progress Report:
The cell repository was maintained for hybridomas producing anti-ricin, anti-abrin, anti-botulinum neurotoxin (BoNT), and anti-staphylococcal enterotoxins A and B (SEA and SEB), and monoclonal antibodies (anti-abrin, ricin, and BoNT) were made available through DHS. An interlaboratory study was published that validated a newly developed immunoassay for ricin detection. Monoclonal antibodies to additional BoNT serotypes, neurotoxin-associated proteins (NAPs), and Shiga toxin 2 (Stx2) were developed. This research progress report addresses objectives 1: Develop new assays for bacterial toxins and their variants, using immunological and other methods, with emphasis on applicability to practical problems facing the food industry and regulatory agencies and 2: Calibrate in vitro methodology against established animal bioassays, and develop new data on the bioavailability of toxins, the impact of food processing on toxin activities, and the significance of antibody-mediated clearance on toxicity, especially via the oral route of intoxication of the parent project.